Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

Kjeld Hermansen; Ronette L Kolotkin; Mette Hammer; Milan Zdravkovic; David Matthews

doi:10.1016/j.pcd.2010.04.001

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

Prim Care Diabetes. 2010 Jul;4(2):113-7. doi: 10.1016/j.pcd.2010.04.001. Epub 2010 May 4.

Authors

Kjeld Hermansen¹, Ronette L Kolotkin, Mette Hammer, Milan Zdravkovic, David Matthews

Affiliation

¹ Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, Denmark. kjelherm@rm.dk

PMID: 20444662
DOI: 10.1016/j.pcd.2010.04.001

Abstract

Patient-reported outcomes for liraglutide or glimepiride on metformin were investigated. Patients' treatment satisfaction on liraglutide was higher than with metformin alone and comparable with glimepiride+metformin. Patients perceived lower frequency of hypoglycaemia than glimepiride+metformin and lower frequency of hyperglycaemia than metformin. Impact of weight on quality of life did not differ.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination
Female
Glucagon-Like Peptide 1 / administration & dosage
Glucagon-Like Peptide 1 / adverse effects
Glucagon-Like Peptide 1 / analogs & derivatives*
Humans
Hypoglycemia / chemically induced
Hypoglycemic Agents / administration & dosage*
Hypoglycemic Agents / adverse effects
Liraglutide
Male
Metformin / administration & dosage*
Metformin / adverse effects
Middle Aged
Patient Satisfaction
Quality of Life
Sulfonylurea Compounds / administration & dosage*
Sulfonylurea Compounds / adverse effects
Treatment Outcome

Substances

Hypoglycemic Agents
Sulfonylurea Compounds
glimepiride
Liraglutide
Glucagon-Like Peptide 1
Metformin